Kathmandu. Nevix Pharmaceuticals Ltd., which is in the process of issuing an initial public offering (IPO) with the Securities Board of Nepal (SEBON), has published a rating of business report for the last fiscal year.

The company had posted an operating income of Rs 11.30 crore as of mid-April of the last FY. Despite the significant increase in the company’s revenue, the profit margin has decreased compared to the previous year.

According to rating agency Infomerics Nepal, the company had posted an operating income of Rs 81.0 million in the fiscal year 2025. The company has been able to increase its revenue in the first nine months of the last fiscal year.

However, the company’s EBITDA margin declined to 27.89 percent in the first nine months of the previous fiscal year from 40.96 percent in FY 2025. This has put pressure on profit margins even though income has increased.

The interest coverage ratio, which measures the company’s interest payment capacity, improved to 1.36 while the current ratio improved to 3.02 from 0.69. Likewise, the total loan-to-EBITDA ratio decreased to 10.69 from 12.85.  This has shown improvement in the management of the company’s financial liabilities.

Headquartered in Pokhara of Kaski, the company’s production plant is located in Byas-10 of Tanahun. As of June 2026, the company has obtained production license for 109 products and marketing license for 78 products. Currently, the company has 72 medicinal products being sold in the Nepali market.

The company’s chief shareholder is Indra Baniya. He owns about 17 percent of the shares in the company. Nivix Pharmaceuticals has applied to the Securities Board of Nepal (SEBON) for an initial public offering (IPO) of 13,75,000 units.

The company has applied to the board for an IPO of Rs 13.75 crore at a face value of Rs 100 per share.  Nepal SBI Merchant Banking Limited has been appointed as the issue manager for the IPO issuance.